Suppr超能文献

位于胆囊管以上的胆管癌中淋巴管侵犯的预后意义:辅助治疗的新选择标准?

The prognostic importance of lymphovascular invasion in cholangiocarcinoma above the cystic duct: a new selection criterion for adjuvant therapy?

机构信息

Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.

出版信息

HPB (Oxford). 2011 Sep;13(9):605-11. doi: 10.1111/j.1477-2574.2011.00335.x. Epub 2011 Jul 26.

Abstract

OBJECTIVE

Criteria for selecting patients to receive adjuvant chemotherapy in cases of resected intrahepatic or hilar cholangiocarcinoma (CC) are lacking. Some clinicians advocate the provision of adjuvant therapy in patients with lymph node (LN)-positive disease; however, nodal assessment is often inadequate. The aim of this study was to identify a surrogate criterion based on primary tumour characteristics.

METHODS

All patients who underwent resection for hilar or intrahepatic CC at a single institution between January 2000 and September 2009 were identified from a prospectively maintained database. Pathological factors were recorded. The primary outcome assessed was overall survival (OS).

RESULTS

In total, 69 patients underwent resection for hilar (n=34) or intrahepatic (n=35) CC. Their median age was 66 years and 27 patients (39%) were male. Median follow-up was 22 months and median OS was 17 months. Median tumour size was 5 cm. Overall, 23% of patients had a positive resection margin, 44% had perineural invasion, 32% had lymphovascular invasion (LVI) and 25% had positive LNs. The median number of LNs removed was two and the median number of positive LNs was zero. The presence of LVI was associated with reduced OS (11.9 months vs. 23.1 months; P=0.023). After accounting for all other adverse tumour factors, the presence of LVI persisted as the only negative prognostic factor for OS on multivariate Cox regression.

CONCLUSIONS

In patients who had undergone resection of hilar or intrahepatic CC, the presence of LVI was strongly associated with reduced OS. Thus the finding of LVI may potentially be used as a criterion in the selection of patients for adjuvant chemotherapy.

摘要

目的

在切除的肝内或肝门部胆管癌(CC)患者中,缺乏选择接受辅助化疗的标准。一些临床医生主张对淋巴结(LN)阳性疾病的患者提供辅助治疗;然而,淋巴结评估往往不足。本研究旨在根据肿瘤特征确定替代标准。

方法

从 2000 年 1 月至 2009 年 9 月期间在一家机构接受肝门部或肝内 CC 切除术的所有患者均从一个前瞻性维护的数据库中确定。记录病理因素。主要评估的结果是总生存(OS)。

结果

共 69 例患者接受了肝门部(n=34)或肝内(n=35)CC 的切除术。他们的中位年龄为 66 岁,27 例(39%)为男性。中位随访时间为 22 个月,中位 OS 为 17 个月。中位肿瘤大小为 5cm。总的来说,23%的患者有阳性切缘,44%的患者有神经周围侵犯,32%的患者有血管淋巴管侵犯(LVI),25%的患者有阳性 LNs。中位数取出的 LNs 数为 2 个,阳性 LNs 数中位数为 0 个。LVI 的存在与 OS 降低相关(11.9 个月比 23.1 个月;P=0.023)。在考虑所有其他不良肿瘤因素后,LVI 的存在在多变量 Cox 回归中仍然是 OS 的唯一负预后因素。

结论

在接受肝门部或肝内 CC 切除术的患者中,LVI 的存在与 OS 降低密切相关。因此,LVI 的发现可能可作为选择辅助化疗患者的标准。

相似文献

3
Staging, prognostic factors and adjuvant therapy of intrahepatic cholangiocarcinoma after curative resection.
Liver Int. 2014 Jul;34(6):953-60. doi: 10.1111/liv.12364. Epub 2013 Nov 20.
4
The prognostic role of lymphovascular invasion and lymph node metastasis in perihilar and intrahepatic cholangiocarcinoma.
Eur J Surg Oncol. 2019 Aug;45(8):1468-1478. doi: 10.1016/j.ejso.2019.04.019. Epub 2019 Apr 25.
6
Prognostic significance of lymph node ratio after resection of peri-hilar cholangiocarcinoma.
HPB (Oxford). 2011 Apr;13(4):240-5. doi: 10.1111/j.1477-2574.2010.00277.x. Epub 2011 Jan 28.

引用本文的文献

1
Recommendations on maximising the clinical value of tissue in the management of patients with intrahepatic cholangiocarcinoma.
JHEP Rep. 2024 Mar 12;6(6):101067. doi: 10.1016/j.jhepr.2024.101067. eCollection 2024 Jun.
2
Prognostic Role of the Intrahepatic Lymphatic System in Liver Cancer.
Cancers (Basel). 2023 Apr 4;15(7):2142. doi: 10.3390/cancers15072142.
4
Prognostic impact of lymphovascular invasion in pT1-T3 gallbladder adenocarcinoma.
J Surg Oncol. 2020 Dec;122(7):1401-1408. doi: 10.1002/jso.26160. Epub 2020 Aug 11.
6
A Novel T-Stage Classification System for Adrenocortical Carcinoma: Proposal from the US Adrenocortical Carcinoma Study Group.
Ann Surg Oncol. 2018 Feb;25(2):520-527. doi: 10.1245/s10434-017-6236-1. Epub 2017 Nov 21.
7
Synchronous Gall Bladder and Bile Duct Cancer: A Short Series of Seven Cases and a Brief Review of Literature.
J Clin Exp Hepatol. 2017 Jun;7(2):115-120. doi: 10.1016/j.jceh.2016.10.003. Epub 2016 Nov 21.
10

本文引用的文献

1
Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment.
J Clin Oncol. 2011 Aug 10;29(23):3140-5. doi: 10.1200/JCO.2011.35.6519. Epub 2011 Jul 5.
3
Surgery and chemotherapy for intrahepatic cholangiocarcinoma.
World J Hepatol. 2010 Feb 27;2(2):58-64. doi: 10.4254/wjh.v2.i2.58.
4
Prognostic relevance of the lymph node ratio in surgical patients with extrahepatic cholangiocarcinoma.
Eur J Surg Oncol. 2011 Jan;37(1):60-4. doi: 10.1016/j.ejso.2010.10.011. Epub 2010 Nov 20.
5
Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma.
Ann Surg Oncol. 2011 Mar;18(3):651-8. doi: 10.1245/s10434-010-1325-4. Epub 2010 Oct 14.
7
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
N Engl J Med. 2010 Apr 8;362(14):1273-81. doi: 10.1056/NEJMoa0908721.
8
Adequate lymph node assessment for extrahepatic bile duct adenocarcinoma.
Ann Surg. 2010 Apr;251(4):675-81. doi: 10.1097/SLA.0b013e3181d3d2b2.
9
Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma.
World J Gastroenterol. 2009 Dec 21;15(47):5976-82. doi: 10.3748/wjg.15.5976.
10
Surgical treatment of hilar cholangiocarcinoma in a new era: comparison among leading Eastern and Western centers, Leeds.
J Hepatobiliary Pancreat Sci. 2010 Jul;17(4):497-504. doi: 10.1007/s00534-009-0203-6. Epub 2009 Oct 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验